Research has shown that certain incretins, such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, interfere with brain regions implicated in Alzheimer’s disease (AD) and Parkinson’s disease (PD). This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.